Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash & Equivalents (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Cash & Equivalents for 5 consecutive years, with $11.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash & Equivalents fell 12.57% year-over-year to $11.4 million, compared with a TTM value of $11.4 million through Dec 2024, down 12.57%, and an annual FY2024 reading of $11.4 million, down 12.57% over the prior year.
  • Cash & Equivalents was $11.4 million for Q4 2024 at Treace Medical Concepts, down from $12.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $119.6 million in Q2 2021 and bottomed at $7.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $41.3 million, with a median of $17.1 million recorded in 2020.
  • The sharpest move saw Cash & Equivalents skyrocketed 1060.81% in 2021, then tumbled 91.78% in 2023.
  • Year by year, Cash & Equivalents stood at $18.1 million in 2020, then surged by 485.39% to $105.8 million in 2021, then plummeted by 81.6% to $19.5 million in 2022, then tumbled by 33.33% to $13.0 million in 2023, then dropped by 12.57% to $11.4 million in 2024.
  • Business Quant data shows Cash & Equivalents for TMCI at $11.4 million in Q4 2024, $12.1 million in Q3 2024, and $18.2 million in Q2 2024.